Revolution Medicines Announces Publication In Cancer Discovery Demonstrating Robust Anti-Tumor Activity Of RAS(ON) Inhibitors In Preclinical Models Of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
Revolution Medicines Announces Publication In Cancer Discovery Demonstrating Robust Anti-Tumor Activity Of RAS(ON) Inhibitors In Preclinical Models Of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC)
發表在《癌症發現》雜誌上的原創研究表明，一種RAS（ON）多選擇性抑制劑在難以治療的KRAS突變的非小細胞肺癌（NSCLC）的臨床前模型中展示了強大的單藥或與RAS（ON）G12C選擇性抑制劑結合的抗腫瘤活性。
Results also highlight that, in contrast to mutant-selective RAS inhibition, broad-spectrum, reversible RAS-GTP inhibition with a RAS(ON) multi-selective inhibitor alone drove durable anti-tumor activity in these models with infrequent resistance occurrence and the potential for emergence of rare persister, slow cycling cells
結果還突顯出，與突變選擇性RAS抑制相比，具有廣譜可逆性的RAS-GTP抑制劑的RAS (ON) 多選擇性抑制劑單獨驅動了這些模型的持久抗腫瘤活性，並且具備罕見持久者和慢速增殖細胞出現的潛力。
REDWOOD CITY, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer-reviewed research paper in Cancer Discovery. The scientific paper demonstrates that the RAS(ON) multi-selective inhibitor RMC-7977 (a preclinical tool compound representative of the investigational drug candidate RMC-6236) exhibited robust and durable anti-tumor activity in multiple preclinical models of KRAS-mutated NSCLC. The data show this activity was further enhanced in the doublet combination with a RAS(ON) G12C-selective inhibitor RMC-4998 (a preclinical tool compound representative of the investigational drug RMC-6291), in preclinical models of KRAS G12C-mutated NSCLC. These findings are the result of original, collaborative research between scientists at Revolution Medicines and The University of Texas MD Anderson Cancer Center.
加利福尼亞州雷德伍德城，2024年7月11日（全球新聞線）--專注於開發針對RAS成癮性癌症患者的靶向治療方案的臨床腫瘤學公司Revolution Medicines， Inc.（納斯達克代碼：RVMD）今日宣佈在《癌症發現》雜誌上發表了一篇同行評議的研究論文。該科學論文證明，RAS（ON）多選擇性抑制劑RMC-7977（作爲研究藥物候選RMC-6236的臨床前示範工具化合物）在多個KRAS突變的非小細胞肺癌（NSCLC）的臨床前模型中展示了強大而持久的抗腫瘤活性。研究數據表明，RAS（ON）G12C選擇性抑制劑RMC-4998（作爲研究藥物RMC-6291的臨床前示範工具化合物）與其雙聯藥物組合後，這種活性被進一步增強。這些發現是Revolution藥物和德克薩斯大學MD安德森癌症中心科學家之間的原創協作研究結果。